Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: Time versus Potency

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4700-4707

  Mejías, Asunción ^a   Chávez Bueno, Susana ^a   Ríos, Ana María ^a   Aten, Mónica Fonseca ^a   Raynor, Brett ^a   Peromingo, Estrella ^a   Soni, Perla ^a   Olsen, Kurt D ^a   Kiener, Peter A ^b   Gómez, Ana María ^a   Jafri, Hasan S ^a   Ramilo, Octavio ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN F; MEDI 524; METHACHOLINE; MONOCLONAL ANTIBODY; NUMAX; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; INFLAMMATION; LONG TERM CARE; LUNG LAVAGE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION;

AIRWAY OBSTRUCTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIAL HYPERREACTIVITY; DISEASE MODELS, ANIMAL; FEMALE; LUNG; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRUS REPLICATION;

EID: 27644485407     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4700-4707.2005     Document Type: Article

References (32)

1. Alvarez, R., K. S. Harrod, W.-J. Shieh, S. Zaki, and R. A. Tripp. 2004. Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. J. Virol. 78:14003-14011.
2. 2003. American Academy of Pediatrics. 2003. 2003 report of the Committee on Infectious Diseases, 26th ed. American Academy of Pediatrics, Elk Grove Village, 111.
3. Boyce, T. G., B. G. Mellen, E. F. Mitchel, Jr., P. F. Wright, and M. R. Griffin. 2000. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J. Pediatr. 137:865-870.
4. Buckingham, S. C., A. J. Bush, and J. P. Devincenzo. 2000. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr. Infect. Dis. J. 19:113-117.
5. Campbell, E. M., S. L. Kunkel, R. M. Stricter, and N. W. Lukacs. 1998. Temporal role of chemokines in a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. J. Immunol. 161:7047-7053.
6. Chavez-Bueno, S., A. Mejias, A. M. Gomez, K. D. Olsen, A. M. Rios, M. Fonseca-Aten, O. Ramilo, and H. S. Jafri. 2005. Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. Virol. J. 2:46.
7. Chunn, J. L., H. W. Young, S. K. Banerjee, G. N. Colasurdo, and M. R. Blackburn. 2001. Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J. Immunol. 167:4676-4685.
8. Connors, M., P. L. Collins, C.-Y. Firestone, and B. R. Murphy. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634-1637.
9. DeVincenzo, J. P., J. Aitken, and L. Harrison. 2003. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J. Pediatr. 143:123-126.
10. DeVincenzo, J. P., C. B. Hall, D. W. Kimberlin, P. J. Sanchez, W. J. Rodriguez, B. A. Jantausch, L. Corey, J. S. Kahn, J. A. Englund, J. A. Suzich, F. J. Palmer-Hill, L. Branco, S. Johnson, N. K. Patel, and F. M. Piazza. 2004. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J. Infect. Dis. 190:975-978.
11. Feltes, T. F., A. K. Cabalka, H. C. Meissner, F. M. Piazza, D. A. Carlin, F. H. Top, Jr., E. M. Connor, and H. M. Sondheimer. 2003. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143:532-540.
12. Hegele, R. G., S. Hayashi, A. M. Bramley, and J. C. Hogg. 1994. Persistence of respiratory syncytial virus genome and protein after acute bronchiolitis in guinea pigs. Chest 105:1848-1854.
13. The IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
14. Jafri, H. S., S. Chavez-Bueno, A. Mejias, A. M. Gomez, A. M. Rios, S. S. Nassi, M. Yusuf, P. Kapur, R. D. Hardy, J. Hatfield, B. B. Rogers, K. Krisher, and O. Ramilo. 2004. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J. Infect. Dis. 189:1856-1865.
15. Johnson, S., C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S. C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, and J. F. Young. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
16. Malley, R., J. DeVincenzo, O. Ramilo, P. H. Dennehy, H. C. Meissner, W. C. Gruber, P. J. Sanchez, H. Jafri, J. Balsley, D. Carlin, S. Buckingham, L. Vernacchio, and D. M. Ambrosino. 1998. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178:1555-1561.
17. Mejías, A., S. Chávez-Bueno, A. M. Ríos, J. Saavedra-Lozano, M. Fonseca Aten, J. Hatfield, P. Kapur, A. M. Gómez, H. S. Jafri, and O. Ramilo. 2004. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob. Agents Chemother. 48:1811-1822.
18. Ottolini, M. G., S. J. Curtis, D. D. Porter, A. Mathews, J. Y. Richardson, V. G. Hemming, and G. A. Prince. 2002. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. 46:2299-2302.
19. Parren, P. W., P. Poignard, H. J. Ditzel, R. A. Williamson, and D. R. Burton. 2000. Antibodies in human infectious disease. Immunol. Res. 21:265-278.
20. Prince, G. A., A. Mathews, S. J. Curtis, and D. D. Porter. 2000. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (Palivizumab) and glucocorticosteroid. J. Infect. Dis. 182:1326-1330.
21. Razinkov, V., C. Huntley, G. Ellestad, and G. Krishnamurthy. 2002. RSV entry inhibitors block F-protein mediated fusion with model membranes. Antivir. Res. 55:189-200.
22. Ríos, A. M., A. Mejías, S. Chávez-Bueno, M. Fonseca-Aten, K. Katz, J. Hatfield, A. M. Gómez, H. S. Jafri, G. H. McCracken, Jr., O. Ramilo, and R. D. Hardy. 2004. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob. Agents Chemother. 48:2897-2904.
23. Saez-Llorens, X., M. T. Moreno, O. Ramilo, P. J. Sanchez, F. H. Top, Jr., and E. M. Connor. 2004. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23:707-712.
24. Schwarze, J., D. R. O'Donnell, A. Rohwedder, and P. J. Openshaw. 2004. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am. J. Respir. Crit. Care Med. 169:801-805.
25. Sigurs, N., P. M. Gustafsson, R. Bjarnason, F. Lundberg, S. Schmidt, F. Sigurbergsson, and B. Kjellman. 2005. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 171:137-141.
26. Spann, K. M., K.-C. Tran, B. Chi, R. L. Rabin, and P. L. Collins. 2004. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J. Virol. 78:4363-4369.
27. Stein, R. T., D. Sherrill, W. J. Morgan, C. J. Holberg, M. Halonen, L. M. Taussig, A. L. Wright, and F. D. Martinez. 1999. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354:541-545.
28. Sullender, W. M. 2000. Respiratory syncytial virus genetic and antigenic diversity. Clin. Microbiol. Rev. 13:1-15.
29. Sullender, W. M., M. A. Mufson, G. A. Prince, L. J. Anderson, and G. W. Wertz. 1998. Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children. J. Infect. Dis. 178:925-932.
30. Tripp, R. A., L. Jones, and L. J. Anderson. 2000. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol. 74:6227-6229.
31. van Woensel, J. B., R. Lutter, M. H. Biezeveld, T. Dekker, M. Nyhuis, W. M. van Aalderen, and T. W. Kuijpers. 2003. Effect of dexamethasone on tracheal viral load and interleukin-8 tracheal concentration in children with respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 22:721-726.
32. Wu, H., D. S. Pfarr, Y. Tang, L. L. An, N. K. Patel, J. D. Watkins, W. D. Huse, P. A. Kiener, and J. F. Young. 2005. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350:126-144.